Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hotel Suite 1 (including C lab extension) 2,238 ft2
Hotel suite 2 2,012 ft2
Labs (PD and QC). 830 ft2
Corridors 1,420 ft2
Computer room 75 ft2
---------------------------------------------------------------
Sub-Total 6,575 ft2
Unfinished and/or un-equipped interior space:
Hotel Suite 3 2,012 ft2
Hotel Suite 4 2,012 ft2
Nitrogen cryostorage area 2,560 ft2
Plant room + electrical cupboard 1,300 ft2
----------------------------------------------------------------
Sub-Total: 7,884 ft2
Total Interior Space: 14,459 ft2
Good point that G-CSF (Neuprogen) will help on the WBC issue..
I would suspect it is already used though. Have no idea how much you can keep feeding the patient and how that effects the nature of the moncytes.
He lives in Chicago?
Come on Stonk, I will gladly bet you or anybody that there is no MAA (or BLA) approval in 2024, Terms of no more posting here.
Yes or no.
Gee hoffman, you make up bet terms and then use your own words as proof. Again, as I have said for almost a yera since your first posted this version of our bet,
I bet double or nothing on the sigline bet that there would not be an approval in 2023
Does continuing to lie about this and posting your own lies in quotes make it true? I guess so for NWBO longs.
Does a link to the actual source documents exist? (I have only seen secondaries)
And again we see Specials running through Dr A. Maybe that is the bottleneck for the waiting line?
BTW, why does Dr A not disclose that it his clinical basically running the MD side of the Specials program? Do you think they do this for free?
If it was somebody on the "other side" failing to disclose the same the longs would be all over it. Yet, all OK here.
There is a fundamental concept in trials called multiplicity and alpha spend is used to control it.
Say you have a trial. Look at one endpoint and it is not P<..05 so you go to the next, then the next. Eventually one works by pure luck. Alpha spend is how you account for multiple endpoints. In this trial the design was that PFS was the primary. If, and only if, it was stat sig then OS would be evaluated.
NWBO learned that PFS failed in 2015 based on the IA (anybody who does not know this is delusional). And so they then changed to OS. That is a basic formal no-no.
That said, the FDA and others may well accepted OS as defined (233 vs 99). But that also failed (and again, anybody who does not know that is delusional). So they changed again to OS vs external controls. But now the issue gets far worse as it is not just a third shot on goal; but also goes against much of what the FDA says in their guidance on how to use ECAs.
Of course you will respond with the NWBO spin on story.
For the record, the Smith vs Cognate lawsuit went to jury with Smith winning and denial of the LP claims of IP theft prior to "WolfGate".
One of the most notable lawsuits was where R Smith sued LP and Cognate for back pay. He won.
LP tried to counter sue for some BS IP theft claim based on a notebook he had not returned. One Court ruled against that and when LP tried again it was dismissed by a second Court.
Why this matters is that this was the case that longs use to assert some BS about NW trying to steal NWBO tech. That story presented by NWBO was all BS to explain why NW, a respected bio investor, was calling out LP for governance issues.
But who cares about the sand in your ears longs.
I would take a swag that the submission is around 1.7M pages * 12k/page for about 20GB.
Now, if NWBO was in the modern world that takes minutes to a couple hours. But if NWBO is using dial up 38.4 modems it would take years.
But have they even said they had all the ,material to the published yet? How can they finalize w/o the input?
232 vs 99. The P3 as designed compared the randomized patients in the 2 arms. The endpoints were PFS and OS between the arms.
The treatment was -L+SOC vs SOC until progression, followed by anything (including -L) after progression. We know the PFS failed badly on that.
More importantly, for the OS 232 vs 99 we do not know as a fact as NWBO elects not to disclose it. We do see solid evidence it looks bad though. And NWBO could always release those numbers if they were not bad.
This is not friggen complicated. When a company runs a randomized P3, the results between the arms count. Crying that the trial was poorly designed is pointless.
The OS 232-99 should have trended well if -L worked even if the crossover confounded it. That is obvious. Yet, NWBO hides that data.
Wow, amazed that Bala and SS do not understand the difference between LL and others researching ATL-DC and NWBO's ongoing scam that is leveraging that research.
Good news though is Advent is close to fully up and running which will produce $150l or so a year rent revenue for NWBO. At least that is better that Cognate where NWBO got nothing.
Actually, I am certain Bala and SS know this.
I do hope good luck for LL, Prins and all on this front.
If one hires a GC to renovate a house and the project keeps going later and later, that is on him regardless of if some sub failed.
Same here. It is on NWBO. If NWBO was generally on time with estimates then a one time excuse would be reasonable. But they are always pathetic on this.
The fail of the Oct 13 PR was comical. Just by looking at what NWBO said for the contractors, NWBO would not be expected to meet the mid-end Nov deadline. Seriously?
But by all means, it is never NWBO's fault. Sure.
And the years go by also. Several anniversaries this month.
1 year ago: Dec 22, 2022 is when NICE restarted the review process.
The first step to get this process going is for NWBO to say they are ready to submit there proposal. The process is is semi public, so we know LP is not going forward yet.
5 years ago: Dec 11,2018 was when NWBO announced the trial was complete
So now you are calling LL a fudster when she asserts in table 1 of the JAMA paper that the median age of teh 232 was NA?
Maybe you should call her and demand a retraction.
BTW, your quote is the median of the 331, not the 232. But who cares.
Of course. That is what is in the ECA of the -L P3. See the footnotes in the JAMA -L paper.
And the ECA patients are the control arm of that (and the other trials).
The JTM paper did not publish any information on the 232 patients who we are talking about.
Again, I am not saying there is any significant age difference. But why did LL not have the median age data on the -L P3? Sounds like she never had anything other than what Dr B provided to her. Odd.
Don;t forget hoffyman's welch on our 2022 bet on revenue.
He was supposed to make a sigline admitting he was wrong. He had that for a weeks before removing it.
And he continually lies about the bet he made with me for this year., It was approval in 2023, and the terms were again a sig line.
Regardless, Steve will live on even if Hoffy departs.
The freezers are already Advent's to use as the please.
Advent has a long term lease for as long as NWBO is in the building. The freezers are part of the building (leashold improvements) thus leased to Advent.,
If and when the lease finally expires the freezers become property of Huawei.
But I like the idea for the ASM. Not that they plan to let shareholders vote this year. The only question is if it is winter or spring.